Patent Oppositions in peptide drugs industry

Explore the competitive field of peptide drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in peptide drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the peptide drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the peptide drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Jun 4, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKMay 6, 2026KRKA
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKMay 5, 2026ZENTIVA
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 28, 2026DEVA HOLDING
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 19, 2026TEVA PHARMACEUTICALS
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 13, 2026ELKINGTON AND FIFE
Oxytocin Receptor Antagonist Therapy In The Luteal Phase For Implantation And Pregnancy In Women Undergoing Assisted Reproductive TechnologiesFERRINGApr 9, 2026JAMES POOLE
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKApr 9, 2026MAIWALD
Compositions And Methods For The Treatment Of Graft Versus Host DiseaseVECTIVBIOApr 2, 2026TEVA PHARMACEUTICALS
Starting Dose Of Pth ConjugatesASCENDIS PHARMA BONE DISEASESApr 1, 2026TEVA PHARMACEUTICALS
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKMar 24, 2026KRAUS & LEDERER PARTGMBB

To stay ahead in the competitive peptide drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the peptide drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Jun 4, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Aug 6, 2025Use Of Long-Acting Glp-1 PeptidesNOVO NORDISK18
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
Dec 18, 2024Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIM11
Aug 10, 2022Semaglutide In Cardiovascular ConditionsNOVO NORDISK8
Nov 3, 2021SyringeNOVARTIS8
Dec 11, 2019Methods Of Treating Hepatic EncephalopathySALIX PHARMACEUTICALS8
Feb 7, 2024Glp-1 Compositions And Uses ThereofNOVO NORDISK8
Feb 7, 2024Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorREGENERON PHARMACEUTICALS7
Sep 13, 2023Compositions Comprising A Delivery Agent And Preparation ThereofNOVO NORDISK7
Aug 7, 2019Methods To Mobilize Progenitor/Stem CellsGENZYME7